METHODS	In both phase III studies ( 301 and 302 ) , levodopa-treated patients were randomized and treated with once-daily oral placebo ( n = 504 ) , perampanel 2 mg ( n = 509 ) , or perampanel 4 mg ( n = 501 ) .\